HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Role of neutralizing anti-murine interleukin-17A monoclonal antibody on chronic ozone-induced airway inflammation in mice.

Abstract
Exposure to ozone has led to airway inflammation and airway hyperresponsiveness, which potential mechanisms relate to ozone-induced oxidative stress. IL-17 is a growing target for autoimmune and inflammatory diseases. The aim of the study was to examine the inhibitory effects of anti-murine interleukin-17A monoclonal antibody (IL-17mAb) on adverse effects of ozone which are noted above. After C57/BL6 mice were exposed to ozone (2.5ppm; 3h) for 12 times over 6 weeks, IL-17mAb, PBS was intraperitoneally injected into mice 1h after ozone or air exposure for 6 weeks and mice were studied 24h after final exposure, monitoring bronchial responsiveness, airway inflammatory cells, lung histology, levels of neutrophil-related chemokine and proinflammatory cytokines in bronchoalveolar lavage (BAL) fluid and serum, the expression of IL-17A mRNA and protein, glucocorticoid receptors (GR), and the phosphorylation of p38MAPK in lung tissues. The administration of IL-17mAb reduced the ozone-induced increases in total cells, especially neutrophils; decreased levels of cytokines, including IL-8 in BAL fluid, IL-8 and IL-17A in serum; mitigated the severity of airway hyperresponsiveness; attenuated lung inflammation scores and histologic analysis confirmed the suppression of lung inflammation, compared with the administration of a control PBS. Exposure to ozone results in increases in IL-17A production rate, mRNA and protein levels of IL-17A and the protein level of GR. These effects were halted and reversed by IL-17mAb treatment. Furthermore, IL-17mAb also reduced the phosphorylation of p38MAPK. Therefore, we conclude that IL-17mAb may be a useful therapy in ozone-related diseases, including COPD.
AuthorsMin Zhang, Xia Fei, Guo-Qing Zhang, Peng-Yu Zhang, Feng Li, Wu-Ping Bao, Ying-Ying Zhang, Xin Zhou
JournalBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (Biomed Pharmacother) Vol. 83 Pg. 247-256 (Oct 2016) ISSN: 1950-6007 [Electronic] France
PMID27380433 (Publication Type: Journal Article)
CopyrightCopyright © 2016 Elsevier Masson SAS. All rights reserved.
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Cytokines
  • Interleukin-17
  • RNA, Messenger
  • Ozone
Topics
  • Animals
  • Antibodies, Monoclonal (pharmacology, therapeutic use)
  • Antibodies, Neutralizing (pharmacology, therapeutic use)
  • Bronchi (drug effects, pathology)
  • Bronchoalveolar Lavage Fluid (cytology)
  • Cell Count
  • Chronic Disease
  • Cytokines (blood)
  • Emphysema (blood, drug therapy, pathology, physiopathology)
  • Interleukin-17 (genetics, immunology, metabolism)
  • Male
  • Mice, Inbred C57BL
  • Ozone
  • Pneumonia (blood, drug therapy, pathology, physiopathology)
  • RNA, Messenger (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: